🇺🇸 FDA
Patent

US 11858941

Heterocyclic and heteroaryl compounds for treating Huntington's disease

granted A61PA61P25/00A61P25/14

Quick answer

US patent 11858941 (Heterocyclic and heteroaryl compounds for treating Huntington's disease) held by PTC THERAPEUTICS, INC. expires Mon Dec 28 2043 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
PTC THERAPEUTICS, INC.
Grant date
Tue Jan 02 2024 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Dec 28 2043 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
16
CPC classes
A61P, A61P25/00, A61P25/14, A61P25/28